PriceTargets.com logo

HilleVax - HLVX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $30.67
  • Forecasted Upside: 155.77%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$11.99 As of 04/26/2024 10:31 AM ET
▼ -0.03 (-0.25%)

This chart shows the closing price for HLVX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New HilleVax Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HLVX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HLVX

Analyst Price Target is $30.67
▲ +155.77% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for HilleVax in the last 3 months. The average price target is $30.67, with a high forecast of $34.00 and a low forecast of $28.00. The average price target represents a 155.77% upside from the last price of $11.99.

This chart shows the closing price for HLVX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in HilleVax. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/21/2024HC WainwrightReiterated RatingBuy ➝ Buy$28.00Low
12/13/2023HC WainwrightInitiated CoverageBuy$28.00Low
11/15/2023GuggenheimLower TargetBuy ➝ Buy$38.00 ➝ $34.00Low
11/10/2023Stifel NicolausLower TargetBuy ➝ Buy$35.00 ➝ $30.00Low
5/24/2022SVB LeerinkInitiated CoverageOutperform$30.00High
5/24/2022GuggenheimInitiated CoverageBuy$40.00High
5/24/2022Stifel NicolausInitiated CoverageBuy$34.00High
5/24/2022JPMorgan Chase & Co.Initiated CoverageOverweight$24.00High
(Data available from 4/26/2019 forward)

News Sentiment Rating

1.34 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2023
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2023
  • 5 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2023
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2024
  • 5 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/26/2024
  • 6 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2024
  • 8 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 8 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

HilleVax logo
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $11.99
Low: $11.99
High: $12.58

50 Day Range

MA: $15.84
Low: $11.86
High: $19.75

52 Week Range

Now: $11.99
Low: $9.94
High: $20.22

Volume

1,768 shs

Average Volume

133,662 shs

Market Capitalization

$596.14 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.65

Frequently Asked Questions

What sell-side analysts currently cover shares of HilleVax?

The following sell-side analysts have issued research reports on HilleVax in the last twelve months: Guggenheim, HC Wainwright, and Stifel Nicolaus.
View the latest analyst ratings for HLVX.

What is the current price target for HilleVax?

3 Wall Street analysts have set twelve-month price targets for HilleVax in the last year. Their average twelve-month price target is $30.67, suggesting a possible upside of 155.1%. Guggenheim has the highest price target set, predicting HLVX will reach $34.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $28.00 for HilleVax in the next year.
View the latest price targets for HLVX.

What is the current consensus analyst rating for HilleVax?

HilleVax currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HLVX will outperform the market and that investors should add to their positions of HilleVax.
View the latest ratings for HLVX.

What other companies compete with HilleVax?

Other companies that are similar to HilleVax include Cabaletta Bio, Mesoblast, Novavax, ProKidney and Prime Medicine. Learn More about companies similar to HilleVax.

How do I contact HilleVax's investor relations team?

The company's listed phone number is 617-213-5054 and its investor relations email address is [email protected]. The official website for HilleVax is www.hillevax.com. Learn More about contacing HilleVax investor relations.